Asthma
54 programs · 51 companies
Programs
54
Companies
51
Trials
45
MOAs
30
GLP-1agKIF18AiHER2C5iAuroraAiMDM2iAHRantBCMA ADCUSP1iCGRPant
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | NDA/BLA | CD19 | ||
| PFE-7550 | Phase 3 | Aβ | ||
| LLY-8903 | Preclinical | CD47 | ||
| DSN-2247 | NDA/BLA | EZH2 | ||
| DSN-791 | NDA/BLA | Aβ | ||
| AMG-415 | Phase 1 | CDK2 | ||
| Capiglumide | Preclinical | CGRP | ||
| Nidaratamab | Phase 3 | FLT3 | ||
| Tixatapinarof | Approved | FGFR | ||
| Tezeratamab | Phase 3 | CGRP | ||
| SGM-3567 | Phase 2/3 | FXIa | ||
| Zoricapivasertib | Phase 2 | HER2 | ||
| Sovaderotide | Phase 2/3 | Menin | ||
| TEM-8322 | Preclinical | IL-23 | ||
| Gelirelsin | Phase 2 | KIF18A | ||
| Mavurasimod | Phase 2 | PCSK9 | ||
| SEO-IIT-935 | Phase 2/3 | GLP-1R | ||
| MSK-IIT-725 | Phase 2/3 | JAK2 | ||
| Ivomavacamten | Phase 1/2 | BET | ||
| CAR-6194 | Preclinical | GLP-1R | ||
| Zanutuximab | Phase 2/3 | USP1 | ||
| Nidafutibatinib | NDA/BLA | EZH2 | ||
| Zorilemzoparlimab | Approved | CDK2 | ||
| NEU-3101 | NDA/BLA | GIP-R | ||
| AMP-8001 | NDA/BLA | PARP | ||
| NGM-3123 | Phase 3 | FcRn | ||
| ACE-6753 | Phase 2/3 | EZH2 | ||
| Capitinib | Phase 1 | C5 | ||
| Capicagene | Approved | TIM-3 | ||
| Elrarasimod | NDA/BLA | TNFα | ||
| INS-9902 | Phase 1/2 | JAK2 | ||
| Ivocilimab | NDA/BLA | VEGF | ||
| FRE-IIT-323 | Phase 2 | APOC3 | ||
| NTR-7700 | Phase 1/2 | Nectin-4 | ||
| Lisonesiran | NDA/BLA | C5 | ||
| Motainavolisib | Phase 1 | CFTR | ||
| Riboosocimab | Phase 2 | TYK2 | ||
| TUR-6841 | Phase 1 | RET | ||
| Talaglumide | NDA/BLA | SGLT2 | ||
| LPC-975 | Phase 2/3 | TNFα | ||
| Sotozanubrutinib | Phase 1/2 | IL-17A | ||
| Ribosotorasib | Approved | HER2 | ||
| EVO-5421 | Preclinical | GLP-1R | ||
| Lisotuximab | Phase 2/3 | FcRn | ||
| ZYD-981 | Preclinical | TIGIT | ||
| Mirisacituzumab | Phase 2 | Aβ | ||
| TEV-8109 | Phase 1 | CD20 | ||
| FUD-IIT-666 | Preclinical | CFTR | ||
| NAT-IIT-836 | NDA/BLA | MALT1 | ||
| Niraratamab | Phase 2/3 | RET | ||
| AVT-4398 | Phase 3 | EZH2 | ||
| Nidarelsin | Phase 2/3 | C5 | ||
| Fixazanubrutinib | Preclinical | EZH2 | ||
| Miriglumide | NDA/BLA | PARP |
Trials (45)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT05167162 | PFE-7550 | Phase 3 | Completed |
| NCT06578825 | PFE-7550 | Phase 3 | Not yet recr... |
| NCT07783922 | PFE-7550 | Phase 3 | Completed |
| NCT07176354 | LLY-8903 | Preclinical | Terminated |
| NCT03371759 | DSN-2247 | NDA/BLA | Completed |
| NCT07047163 | DSN-791 | NDA/BLA | Terminated |
| NCT06643642 | Capiglumide | Preclinical | Recruiting |
| NCT05290739 | Capiglumide | Preclinical | Recruiting |
| NCT07679587 | Nidaratamab | Phase 3 | Active |
| NCT04085450 | Tixatapinarof | Approved | Recruiting |
| NCT07650272 | Tixatapinarof | Approved | Not yet recr... |
| NCT04844680 | Tixatapinarof | Approved | Completed |
| NCT03412060 | Tezeratamab | Phase 3 | Active |
| NCT04117299 | SGM-3567 | Phase 2/3 | Not yet recr... |
| NCT06957588 | Zoricapivasertib | Phase 2 | Recruiting |
| NCT03346847 | TEM-8322 | Preclinical | Terminated |
| NCT05007528 | TEM-8322 | Preclinical | Not yet recr... |
| NCT08438714 | SEO-IIT-935 | Phase 2/3 | Active |
| NCT08355629 | MSK-IIT-725 | Phase 2/3 | Active |
| NCT03949276 | Ivomavacamten | Phase 1/2 | Completed |